Tirzepatide: Mechanism of Action

1. Alvo Receptor Primarios — Dual GIP/GLP-1 Agonism

Tirzepatide is a first-in-class unimolecular dual agonist que simultaneamente direciona the dependente de glicose insulinotropic polypeptide (GIP) receptor e o(a) glucagon-like peptide-1 (GLP-1) receptor. [1] It funciona como um agonista desequilibrado: afinidade de ligacao para o(a) GIP receptor equals aquele(a) de native GIP, enquanto GLP-1 receptor affinity is aproximadamente 5- to 13-fold weaker do que native GLP-1. [6] Cryo-electron microscopy confirma the N-terminus of tirzepatide (Tyr1) forms hydrogen bonds with GLP-1R residues (e.g., Gln234), enquanto Glu3 forms ionic bonds with Arg190, with analogous interactions no(a) GIPR. [8]

2. Biased Agonism — cAMP Over β-Arrestin

Diferentemente de native GLP-1 que recruits ambos(as) G-proteins and β-arrestin, tirzepatide exibe biased agonism no(a) GLP-1 receptor: it preferentially ativa cyclic adenosine monophosphate (cAMP) generation enquanto inducing significantly lower β-arrestin recruitment. [9] This reduz receptor internalizacao and dessensibilizacao, maintaining GLP-1R availability no(a) cell surface for prolonged signaling. At the GIP receptor, tirzepatide mimics the signaling profile of native GIP. [10]

3. Sinalizacao a Jusante — cAMP/PKA, PI3K/AKT, AMPK, NF-κB

Binding to GIP/GLP-1 receptors inicia varios(as) key intracellular cascades: [11]

• cAMP/PKA Pathway: Upregulou intracellular cAMP ativa Protein Kinase A, stimulating dependente de glicose secrecao de insulina from pancreatic β-cells.
• PI3K/AKT Pathway: Enhances funcao mitocondrial, reduz neuroinflamacao, and promove sobrevivencia celular.
• AMPK Pathway: Activated in CNS and periferico(a) tissues, linked to metabolic regulacao and energy homeostasis.
• NF-κB Inhibition: Suppresses the TLR4/NF-κB/NLRP3 inflammasome pathway, reducing pro-inflamatorio(a) cytokines (TNF-α, IL-6). [12]
• CREB/BDNF Pathway: In neuronal cells, ativa pAkt/CREB/BDNF signaling para promover neuronal growth and survival. [13]

4. Tissue-Level Effects

Pancreas: Enhances ambos(as) first- and second-phase insulin secretion in a dependente de glicose manner. Reduces fasting and postprandial glucagon secretion during hiperglicemia enquanto preserving glucagonotropic function during hipoglicemia. [14]

Adipose Tissue: GIP receptor agonism melhora sensibilidade a insulina in tecido adiposo, aumenta adiponectin levels by 16–26%, and aprimora lipid buffering via aumentou lipoprotein lipase (LPL) activity. [15]

CNS: Acts no(a) hypothalamus para regular appetite and satiety. Animal research (Bossi et al., 2025) indica tirzepatide temporarily aumenta energy expenditure shortly after dosing, diferentemente de semaglutide que initially reduz it. [16]

Liver: Reduces liver fat content and stiffness; no(a) SYNERGY-NASH trial, resolved MASH sem worsening fibrose in up to 62% of participants. [17]

5. Pharmacokinetics — Once-Weekly Dosing

A C20 fatty diacid enables 99% albumin binding, yielding a meia-vida of ~5 days (116.7 hours), biodisponibilidade of ~80% SC, T_max of 8–72 hours, and V_d of ~10.3 L. [3] Metabolism occurs via proteolytic cleavage, β-oxidation do(a) fatty diacid moiety, and amide hidrolise. Metabolites are excreted via urine and feces. [18]

6. Dose-Response Relationships

Clinical trials demonstrate clear dose-dependente efficacy across all indications: [19]

• HbA1c (SURPASS-1): −1.87% (5 mg), −1.89% (10 mg), −2.07% (15 mg)
• Weight loss (SURMOUNT-1): −15.0% (5 mg), −19.5% (10 mg), −20.9% (15 mg)
• MASH resolution (SYNERGY-NASH): 44% (5 mg), 56% (10 mg), 62% (15 mg)